A systematic review of oral methotrexate for multiple sclerosis

Abstract

Oral methotrexate is a potent immunosuppressant, which could have a beneficial effect on relapse rates and delay disease progression in multiple sclerosis (MS). We performed a systematic review of all randomized controlled trials of oral methotrexate for MS. Of the two randomized controlled trials identified, one was excluded due to its allocation concealment and definition of a relapse and time to sustained disease progression. The other trial studied 60 participants with progressive MS only. This trial reported a non-significant reduction in sustained Expanded Disability Status Scale (EDSS) progression and number of relapses in favour of methotrexate therapy. There were no data on relapse rate and no difference in time to first relapse. Minor side-effects were reported in both methotrexate (87.1%) and placebo groups (89.7%), but there were no major side-effects. Further trials are required in both relapsing-remitting and progressive groups to establish the role of oral methotrexate in MS.

Keywords

immunomodulatory drugs multiple sclerosis oral methotrexate systematic review

Get full access to this article

View all access options for this article.

References

Markovic-Plese S , Pinilla C , Martin R. The initiation of the autoimmune response in multiple sclerosis . Clin Neurol Neurosurg 2004; 106(3): 218-222 .

Segal R , Yaron M , Tartakovsky B. Methotrexate: mechanism of action in rheumatoid arthritis . Semin Arthritis Rheum 1990; 20: 190-200 .

Cronstein B , Naime D , Ostad E. The anti-inflammatory effects of methotrexate . J Clin Inv 1993; 92: 2675-2682 .

Sperling RI , Benincaso AI , Anderson RJ , Coblyn JS , Austen KF , Weinblatt ME. Acute and chronic suppression of leukotriene B4 ex vivo in neutrophils from patients with rheumatoid arthritis beginning treatment with methotrexate . Arthritis Rheum 1992; 35: 376-384 .

Neilsen HJ , Hammer JH. Possible role of histamine in pathogenesis of autoimmune diseases: implications for immunotherapy with histamine-2 receptor antagonists . Med Hypotheses 1992; 39: 349-355 .

Colsky J , Greenspan E , Warren T. Hepatic fibrosis in children with acute leukaemia after therapy with folate antagonists . Arch Pathol 1955; 59: 198-206 .

Ahern MJ , Smith MD , Roberts-Thompson PJ. Methotrexate hepatotoxicity: what is the evidence ? Inflamm Res 1998; 47: 148-151 .

Gray O , McDonnell GV , Forbes RB. Methotrexate for multiple sclerosis (Cochrane Review) . The Cochrane Library, Issue 1. John Wiley & Sons Ltd. , 2005.

Poser CM , Paty DW , Scheinberg L , McDonald I , Davis FA , Ebers GC et al. New diagnostic criteria for multiple sclerosis: guidelines for research protocols . Ann Neurol 1983; 13: 227-231 .

10.

Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an Expanded Disability Status Scale . Neurology 1983; 33: 1444-1452 .

11.

Currier RD , Haerer AF , Meydrech EF. Low dose oral methotrexate treatment of multiple sclerosis: a pilot study . J Neurol Neurosurg Psychiatry 1993; 56: 1217-1218 .

12.

Goodkin DE , Rudick RA , VanderBrug Medendorp S , Daughtry MM , Schwetz KM , Fischer J et al. Low dose (7.5 mg) oral methotrexate reduces the rate of progression in chronic progressive multiple sclerosis . Ann Neurol 1995; 37: 30-40 .